CA3234484A1 - Oxysterols and methods of use thereof - Google Patents
Oxysterols and methods of use thereof Download PDFInfo
- Publication number
- CA3234484A1 CA3234484A1 CA3234484A CA3234484A CA3234484A1 CA 3234484 A1 CA3234484 A1 CA 3234484A1 CA 3234484 A CA3234484 A CA 3234484A CA 3234484 A CA3234484 A CA 3234484A CA 3234484 A1 CA3234484 A1 CA 3234484A1
- Authority
- CA
- Canada
- Prior art keywords
- substituted
- disorder
- unsubstituted
- alkyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662409767P | 2016-10-18 | 2016-10-18 | |
| US201662409761P | 2016-10-18 | 2016-10-18 | |
| US201662409774P | 2016-10-18 | 2016-10-18 | |
| US201662409764P | 2016-10-18 | 2016-10-18 | |
| US201662409772P | 2016-10-18 | 2016-10-18 | |
| US62/409,772 | 2016-10-18 | ||
| US62/409,761 | 2016-10-18 | ||
| US62/409,764 | 2016-10-18 | ||
| US62/409,767 | 2016-10-18 | ||
| US62/409,774 | 2016-10-18 | ||
| CA3041088A CA3041088C (en) | 2016-10-18 | 2017-10-18 | Oxysterols and methods of use thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3041088A Division CA3041088C (en) | 2016-10-18 | 2017-10-18 | Oxysterols and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3234484A1 true CA3234484A1 (en) | 2018-04-26 |
Family
ID=60263023
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3041088A Active CA3041088C (en) | 2016-10-18 | 2017-10-18 | Oxysterols and methods of use thereof |
| CA3234484A Pending CA3234484A1 (en) | 2016-10-18 | 2017-10-18 | Oxysterols and methods of use thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3041088A Active CA3041088C (en) | 2016-10-18 | 2017-10-18 | Oxysterols and methods of use thereof |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11149054B2 (OSRAM) |
| EP (2) | EP3529257B1 (OSRAM) |
| JP (4) | JP7118957B2 (OSRAM) |
| KR (2) | KR102583278B1 (OSRAM) |
| CN (4) | CN119350419A (OSRAM) |
| AU (3) | AU2017345400B2 (OSRAM) |
| BR (1) | BR112019008032A2 (OSRAM) |
| CA (2) | CA3041088C (OSRAM) |
| DK (1) | DK3529257T3 (OSRAM) |
| ES (1) | ES2952106T3 (OSRAM) |
| IL (2) | IL266093B2 (OSRAM) |
| MA (1) | MA46566A (OSRAM) |
| MX (4) | MX2019004578A (OSRAM) |
| RU (1) | RU2019115113A (OSRAM) |
| TW (3) | TW202444381A (OSRAM) |
| WO (1) | WO2018075699A1 (OSRAM) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6205362B2 (ja) | 2011-09-08 | 2017-09-27 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性のステロイド、組成物、およびそれらの使用 |
| SMT201800657T1 (it) | 2013-03-13 | 2019-01-11 | Sage Therapeutics Inc | Steroidi neuroattivi e loro metodi di utilizzo |
| ES2970222T3 (es) | 2014-06-18 | 2024-05-27 | Sage Therapeutics Inc | Oxiesteroles y procedimientos de uso de los mismos |
| SG10202002655VA (en) | 2015-07-06 | 2020-05-28 | Sage Therapeutics Inc | Oxysterols and methods of use thereof |
| SMT202100226T1 (it) | 2015-07-06 | 2021-05-07 | Sage Therapeutics Inc | Ossisteroli e metodi di uso degli stessi |
| PL3436022T3 (pl) * | 2016-04-01 | 2022-08-08 | Sage Therapeutics, Inc. | Oksysterole i sposoby ich stosowania |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| HUE055263T2 (hu) | 2016-07-07 | 2021-11-29 | Sage Therapeutics Inc | 11-Szubsztituált 24-hidroxiszterolok NMDA-hoz kapcsolódó állapotok kezelésére |
| ES2935057T3 (es) | 2016-09-30 | 2023-03-01 | Sage Therapeutics Inc | C7 oxisteroles sustituidos y estos compuestos para su uso como moduladores de la NMDA |
| ES3038660T3 (en) | 2016-10-18 | 2025-10-14 | Sage Therapeutics Inc | Oxysterols and methods of use thereof |
| CN119350419A (zh) | 2016-10-18 | 2025-01-24 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
| WO2020260558A1 (en) | 2019-06-27 | 2020-12-30 | Phenex Pharmaceuticals Ag | 3-modified iso-/isoallo-lithocholic acid derivatives or their homo-analogs for preventing and treating clostridioides difficile-associated diseases |
| GB201913752D0 (en) | 2019-09-24 | 2019-11-06 | Syngenta Crop Protection Ag | Herbicidal compounds |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| GB201914277D0 (en) | 2019-10-03 | 2019-11-20 | Syngenta Crop Protection Ag | Herbicidal compounds |
| GB201917898D0 (en) | 2019-12-06 | 2020-01-22 | Syngenta Crop Protection Ag | Herbicidal compounds |
| EP4171502A4 (en) * | 2020-06-26 | 2025-02-19 | Durect Corporation | Use of oxygenated cholesterol sulfates for treating inflammatory conditions |
| JP2024520805A (ja) | 2021-06-11 | 2024-05-24 | セージ セラピューティクス， インコーポレイテッド | アルツハイマー病の治療のための神経活性ステロイド |
| WO2023049295A1 (en) | 2021-09-22 | 2023-03-30 | Sage Therapeutics, Inc. | Deuterated positive nmda-modulating compounds and methods of use thereof |
| WO2023083979A1 (en) * | 2021-11-10 | 2023-05-19 | Umecrine Ab | 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor |
| EP4447953A1 (en) | 2021-12-13 | 2024-10-23 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
| CN116143859A (zh) * | 2022-12-09 | 2023-05-23 | 江苏佳尔科药业集团股份有限公司 | 5α-孕甾-3,20-二酮的制备方法 |
| WO2025221731A1 (en) * | 2024-04-15 | 2025-10-23 | Sage Therapeutics, Inc. | Nmda receptor-modulating compounds and methods of use thereof |
Family Cites Families (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2259698A (en) | 1938-05-07 | 1941-10-21 | Rare Chemicals Inc | Physiologically effective substance and process of preparing same |
| US2594323A (en) | 1948-07-22 | 1952-04-29 | Upjohn Co | 24-substituted delta 5-cholene-3, 24-diols |
| US3079385A (en) | 1961-01-24 | 1963-02-26 | Roussel Uclaf | Novel process of preparation of polyhydroxylated pregnanes |
| US3206459A (en) | 1962-10-19 | 1965-09-14 | Syntex Corp | 10alpha-pregnan-19-ol derivatives |
| JPS5324071B2 (OSRAM) | 1974-04-30 | 1978-07-18 | ||
| US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
| CH628907A5 (en) | 1975-10-10 | 1982-03-31 | Hoffmann La Roche | Process for the preparation of 24,25-dihydroxycholesterol derivatives |
| JPS5382766U (OSRAM) | 1976-12-11 | 1978-07-08 | ||
| JPS5840960B2 (ja) | 1976-12-28 | 1983-09-08 | 帝人株式会社 | ヒドロキシコレステロ−ル立体異性体間の相互変換法 |
| JPS5758506Y2 (OSRAM) | 1978-05-09 | 1982-12-14 | ||
| JPS54156176A (en) | 1978-05-30 | 1979-12-08 | Matsushita Electric Industrial Co Ltd | Method of producing circuit pattern punched die for printed circuit |
| JPS54163565A (en) | 1978-06-09 | 1979-12-26 | Teijin Ltd | 24*255epoxyy3beta * 266 dihydroxyychlestoo55ene or protected derivative of hydroxyl group thereof and production |
| JPS5735597A (en) | 1980-08-13 | 1982-02-26 | Teijin Ltd | 25,26-epoxy-3beta,24-dihydroxycholest-5-ene or its hydroxyl- protected derivative and their preparation |
| JPS61254599A (ja) | 1985-05-07 | 1986-11-12 | Sumitomo Pharmaceut Co Ltd | コレステロ−ルのフツ素誘導体 |
| JPS62187485A (ja) | 1986-02-13 | 1987-08-15 | Teijin Ltd | ２４，２５−エポキシコレステロ−ル類の製造法 |
| JPS62187485U (OSRAM) | 1986-05-15 | 1987-11-28 | ||
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| DE69435286D1 (de) | 1993-05-24 | 2010-05-20 | Purdue Pharma Ltd | Verfahren und zusammensetzungen zum hervorrufen von schlaf |
| IL110309A0 (en) | 1993-07-15 | 1994-10-21 | Univ Kentucky Res Found | A method of protecting against neuron loss |
| EP0752860B1 (en) | 1994-02-14 | 2000-08-23 | Euro-Celtique S.A. | Androstanes and pregnanes for allosteric modulation of gaba receptor |
| TW385308B (en) | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
| US5595996A (en) | 1994-10-25 | 1997-01-21 | Merck & Co., Inc. | 7-substituted 4-aza cholanic acid derivatives and their use |
| CA2205919A1 (en) | 1994-11-23 | 1996-05-30 | Cocensys, Inc. | Androstane and pregnane series for allosteric modulation of gaba receptor |
| JPH08268917A (ja) | 1995-03-31 | 1996-10-15 | D D S Kenkyusho:Kk | 癌組織への移行性の高い制癌剤 |
| DE69634039T2 (de) | 1995-06-06 | 2005-12-08 | Euro-Celtique S.A. | Steroidderivate der Androstan- und der Pregnanreihe |
| US5792635A (en) | 1995-06-07 | 1998-08-11 | Magainin Pharmaceuticals, Inc. | Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine |
| US6645953B2 (en) | 1995-06-23 | 2003-11-11 | Novo Nordisk A/S | Meiosis regulating compounds |
| RU2182909C2 (ru) | 1995-06-23 | 2002-05-27 | Ново Нордиск А/С | Стероиды, способ регулирования мейоза |
| US5888996A (en) | 1995-07-26 | 1999-03-30 | Trustees Of Boston University | Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity |
| WO1997003677A1 (en) | 1995-07-24 | 1997-02-06 | Trustees Of Boston University | Inhibition of nmda receptor activity by pregnenolone sulfate derivatives |
| JPH09328498A (ja) | 1996-06-10 | 1997-12-22 | Teijin Ltd | ２４，２５−ジヒドロキシコレステロールの製造法およびその合成中間体 |
| WO1998005337A1 (en) | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| US6122371A (en) | 1997-07-22 | 2000-09-19 | Atwell; Ronald C. | Apparatus for protecting coin-operated telephones from vandalism and larceny |
| CA2331299A1 (en) | 1998-05-11 | 1999-11-18 | Novo Nordisk A/S | Substituted guanidines and diaminonitroethenes, their preparation and use |
| KR20010043558A (ko) | 1998-05-13 | 2001-05-25 | 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 | 감수분열 조절 화합물 |
| US8541600B2 (en) | 1998-11-24 | 2013-09-24 | Harbor Therapeutics, Inc. | 11-aza, 11-thia and 11-oxa sterol compounds and compositions |
| GB9910934D0 (en) | 1999-05-11 | 1999-07-14 | Res Inst Medicine Chem | Chemical compounds |
| CN1098273C (zh) | 1999-11-12 | 2003-01-08 | 中国科学院上海有机化学研究所 | 高立体选择性的合成24r,25－和24s,25－二羟基甾体化合物 |
| GB0000228D0 (en) | 2000-01-06 | 2000-03-01 | Phytopharm Plc | Fluoro substituted sapogenins and their use |
| GB0019290D0 (en) | 2000-08-04 | 2000-09-27 | Symphar Sa | Methods for inducing apolipoprotein E secretion |
| GR1003861B (el) | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
| GB0107822D0 (en) | 2001-03-28 | 2001-05-23 | Phytopharm Plc | Sapogenin derivatives their synthesis and use methods based upon their use |
| EP1392713B1 (en) | 2001-05-03 | 2007-10-17 | The University of Chicago | Liver x receptor agonists |
| US20070197484A1 (en) | 2001-05-03 | 2007-08-23 | Ching Song | Method of treating disorder related to high cholesterol concentration |
| CA2466033A1 (en) | 2001-11-08 | 2003-05-15 | The University Of Chicago | Method of treating disorder related to high cholesterol concentration |
| AU2002360489A1 (en) | 2001-12-07 | 2003-06-23 | The Regents Of The University Of California | Treatment for age-related macular degeneration |
| PL213697B1 (pl) | 2002-03-27 | 2013-04-30 | Phytopharm Plc | Substancje czynne do stosowania w leczeniu chorób, zwlaszcza chorób neurodegeneracyjnych |
| CN102727501A (zh) | 2002-03-27 | 2012-10-17 | 菲特法姆股份有限公司 | 皂角苷配基及其衍生物的用途 |
| JP2004012949A (ja) | 2002-06-10 | 2004-01-15 | Canon Inc | 電気泳動表示装置 |
| US6933312B2 (en) | 2002-10-07 | 2005-08-23 | Agouron Pharmaceuticals, Inc. | Pyrazole derivatives |
| WO2004055201A2 (en) | 2002-12-13 | 2004-07-01 | Bayer Healthcare Ag | Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease |
| FR2850023B1 (fr) | 2003-01-17 | 2007-04-06 | Mapreg | Medicaments pour le systeme nerveux |
| GB0403889D0 (en) | 2004-02-21 | 2004-03-24 | Univ Edinburgh | Uses of er-beta modulators |
| WO2006037016A2 (en) | 2004-09-27 | 2006-04-06 | The Regents Of The University Of California | Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| US20070032464A1 (en) | 2004-10-08 | 2007-02-08 | Shutsung Liao | Methods of treating cancers |
| KR101358078B1 (ko) | 2004-11-01 | 2014-02-06 | 주식회사 유스팜인터내셔널 | 근위축성 측삭 경화증의 신경퇴행을 감소시키기 위한 방법및 조성물 |
| WO2007098281A2 (en) | 2006-02-27 | 2007-08-30 | Regents Of The University Of California | Oxysterol compounds and the hedgehog pathway |
| CN101164540A (zh) | 2006-08-03 | 2008-04-23 | 中山大学 | 海洋甾体化合物在制备治疗神经元损伤药物中的应用 |
| US8273747B2 (en) | 2006-11-02 | 2012-09-25 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
| PL2711371T3 (pl) | 2006-11-21 | 2018-06-29 | Asarina Pharma Ab | Zastosowanie steroidów pregnanowych i androstanowych do wytwarzania kompozycji farmaceutycznej do leczenia zaburzeń oun |
| WO2008157786A1 (en) | 2007-06-20 | 2008-12-24 | Auspex Pharmaceutical, Inc. | Substituted n-aryl pyridinones as fibrotic inhibitors |
| GB0712494D0 (en) | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
| US20110118353A1 (en) | 2007-11-06 | 2011-05-19 | N. V. Organon | Method of hormone suppression in humans |
| WO2009090063A1 (en) | 2008-01-16 | 2009-07-23 | Jado Technologies Gmbh | Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases |
| NZ589764A (en) | 2008-05-09 | 2012-10-26 | Univ Emory | NMDA receptor antagonists for the treatment of neuropsychiatric disorders |
| WO2010065709A2 (en) | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
| US20120040916A1 (en) | 2008-12-22 | 2012-02-16 | Massachusetts Institute Of Technology | Molecular inhibitors of the wnt/beta-catenin pathway |
| US20110319416A1 (en) | 2009-01-28 | 2011-12-29 | Emory University | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions |
| EP2459581A4 (en) | 2009-07-29 | 2012-12-26 | Univ Chicago | LIVER X-RECEPTOR AGONISTS |
| WO2011028794A2 (en) | 2009-09-01 | 2011-03-10 | Lazarus Therapeutics, Inc. | Treatment of huntington's disease with cycloserine and an nmda receptor antagonist |
| FR2953138B1 (fr) | 2009-12-02 | 2015-10-16 | Assist Publ Hopitaux Marseille | Composes aminosteroidiens pour une application topique locale pour la decolonisation cutaneo-muqueuse de staphylococcus aureus |
| GB2467232B (en) * | 2010-01-25 | 2011-02-23 | Crane Electronics | Variable torque-rate test joint |
| KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| US20120035156A1 (en) | 2010-08-09 | 2012-02-09 | Daniela Alberati | Combination of glyt1 compound with antipsychotics |
| US8969525B2 (en) | 2010-11-09 | 2015-03-03 | Enzo Life Sciences, Inc. | Hydroxycholesterol immunoassay |
| WO2012142039A1 (en) | 2011-04-15 | 2012-10-18 | University Of North Dakota | Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases |
| CA2874998A1 (en) | 2011-05-27 | 2012-12-06 | Cytocure Llc | Methods, compositions, and kits for the treatment of cancer |
| EP2736919A4 (en) | 2011-07-29 | 2015-01-14 | Univ California | NEW 17-BETA-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS |
| JP6205362B2 (ja) * | 2011-09-08 | 2017-09-27 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性のステロイド、組成物、およびそれらの使用 |
| CN104136452A (zh) | 2011-10-14 | 2014-11-05 | 萨奇治疗股份有限公司 | 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途 |
| US20150119327A1 (en) | 2012-04-25 | 2015-04-30 | The Regents Of The University Of California | Drug screening platform for rett syndrome |
| WO2014025942A1 (en) | 2012-08-09 | 2014-02-13 | Emory University | Nmda receptor modulators and uses related thereto |
| WO2014028942A2 (en) | 2012-08-17 | 2014-02-20 | Trueex Group Llc | Interoffice bank offered rate financial product and implementation |
| RS57390B1 (sr) | 2012-12-18 | 2018-09-28 | Univ Washington | Neuroaktivni 19-alkoksi-17-supstituisani steroidi, primenjivi u postupcima lečenja |
| JP2016505038A (ja) | 2013-01-23 | 2016-02-18 | スファエラ ファーマ プライベート リミテッド | ミトコンドリア生合成ならびにミトコンドリア機能不全または欠乏に関連する疾患において使用するための１１β−ヒドロキシステロイドの新規の化合物 |
| EA031905B1 (ru) | 2013-01-29 | 2019-03-29 | Аптиникс Инк. | Спиролактамные модуляторы рецептора nmda и их применение |
| SMT201800657T1 (it) * | 2013-03-13 | 2019-01-11 | Sage Therapeutics Inc | Steroidi neuroattivi e loro metodi di utilizzo |
| AU2014243819A1 (en) | 2013-03-13 | 2015-10-01 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| EP3049089B1 (en) | 2013-09-25 | 2019-08-21 | Van Andel Research Institute | Highly potent glucocorticoids |
| ES2970222T3 (es) | 2014-06-18 | 2024-05-27 | Sage Therapeutics Inc | Oxiesteroles y procedimientos de uso de los mismos |
| US10238664B2 (en) | 2014-07-09 | 2019-03-26 | Duke University | Compositions and methods for the repair of myelin |
| CN107405352A (zh) | 2014-10-07 | 2017-11-28 | 萨奇治疗股份有限公司 | 神经活性化合物及其使用方法 |
| SG10202002655VA (en) | 2015-07-06 | 2020-05-28 | Sage Therapeutics Inc | Oxysterols and methods of use thereof |
| SMT202100226T1 (it) | 2015-07-06 | 2021-05-07 | Sage Therapeutics Inc | Ossisteroli e metodi di uso degli stessi |
| EP3319610A4 (en) | 2015-07-06 | 2019-03-06 | Sage Therapeutics, Inc. | OXYSTEROLS AND METHOD OF USE THEREOF |
| GB2557875A (en) | 2015-09-02 | 2018-07-04 | Univ Swansea | Diagnostic methods and kits |
| PL3436022T3 (pl) | 2016-04-01 | 2022-08-08 | Sage Therapeutics, Inc. | Oksysterole i sposoby ich stosowania |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| HUE055263T2 (hu) | 2016-07-07 | 2021-11-29 | Sage Therapeutics Inc | 11-Szubsztituált 24-hidroxiszterolok NMDA-hoz kapcsolódó állapotok kezelésére |
| NZ790187A (en) | 2016-07-11 | 2025-08-29 | Sage Therapeutics Inc | C7, C12, and C16 substituted neuroactive steroids and their methods of use |
| ES2935057T3 (es) | 2016-09-30 | 2023-03-01 | Sage Therapeutics Inc | C7 oxisteroles sustituidos y estos compuestos para su uso como moduladores de la NMDA |
| ES3038660T3 (en) | 2016-10-18 | 2025-10-14 | Sage Therapeutics Inc | Oxysterols and methods of use thereof |
| CN119350419A (zh) | 2016-10-18 | 2025-01-24 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
| AU2018234828A1 (en) | 2017-03-15 | 2019-09-19 | Modernatx, Inc. | Lipid nanoparticle formulation |
| CN110945006A (zh) | 2017-06-23 | 2020-03-31 | 英特塞普特医药品公司 | 用于制备胆汁酸衍生物的方法和中间体 |
| SG10202110563YA (en) | 2017-11-10 | 2021-11-29 | Marinus Pharmaceuticals Inc | Ganaxolone for use in treating genetic epileptic disoders |
-
2017
- 2017-10-18 CN CN202411361474.9A patent/CN119350419A/zh active Pending
- 2017-10-18 AU AU2017345400A patent/AU2017345400B2/en active Active
- 2017-10-18 IL IL266093A patent/IL266093B2/en unknown
- 2017-10-18 CN CN201780077719.7A patent/CN110267966B/zh active Active
- 2017-10-18 DK DK17794489.9T patent/DK3529257T3/da active
- 2017-10-18 TW TW113112851A patent/TW202444381A/zh unknown
- 2017-10-18 TW TW106135757A patent/TWI815800B/zh active
- 2017-10-18 ES ES17794489T patent/ES2952106T3/es active Active
- 2017-10-18 MX MX2019004578A patent/MX2019004578A/es unknown
- 2017-10-18 US US16/343,235 patent/US11149054B2/en active Active
- 2017-10-18 WO PCT/US2017/057277 patent/WO2018075699A1/en not_active Ceased
- 2017-10-18 TW TW111135365A patent/TWI892042B/zh active
- 2017-10-18 RU RU2019115113A patent/RU2019115113A/ru unknown
- 2017-10-18 BR BR112019008032-5A patent/BR112019008032A2/pt active Search and Examination
- 2017-10-18 JP JP2019520736A patent/JP7118957B2/ja active Active
- 2017-10-18 CN CN202210676312.9A patent/CN115181153A/zh active Pending
- 2017-10-18 KR KR1020197014199A patent/KR102583278B1/ko active Active
- 2017-10-18 CA CA3041088A patent/CA3041088C/en active Active
- 2017-10-18 MA MA046566A patent/MA46566A/fr unknown
- 2017-10-18 CA CA3234484A patent/CA3234484A1/en active Pending
- 2017-10-18 CN CN202210185374.XA patent/CN114478677B/zh active Active
- 2017-10-18 EP EP17794489.9A patent/EP3529257B1/en active Active
- 2017-10-18 EP EP23171489.0A patent/EP4252848A3/en active Pending
- 2017-10-18 KR KR1020237032535A patent/KR20230142639A/ko not_active Ceased
- 2017-10-18 IL IL297804A patent/IL297804A/en unknown
-
2019
- 2019-04-17 MX MX2022012317A patent/MX2022012317A/es unknown
- 2019-04-17 MX MX2022012313A patent/MX2022012313A/es unknown
- 2019-04-17 MX MX2021013075A patent/MX2021013075A/es unknown
-
2021
- 2021-08-05 US US17/395,155 patent/US11851457B2/en active Active
-
2022
- 2022-02-10 AU AU2022200884A patent/AU2022200884B2/en active Active
- 2022-03-14 JP JP2022039315A patent/JP2022069555A/ja not_active Withdrawn
-
2023
- 2023-11-09 US US18/388,390 patent/US20240199682A1/en active Pending
-
2024
- 2024-01-25 JP JP2024009591A patent/JP2024028631A/ja active Pending
- 2024-04-29 AU AU2024202774A patent/AU2024202774A1/en active Pending
-
2025
- 2025-06-10 JP JP2025097029A patent/JP2025123284A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11851457B2 (en) | Oxysterols and methods of use thereof | |
| US11613556B2 (en) | Oxysterols and methods of use thereof | |
| EP3519422B1 (en) | C7 substituted oxysterols and these compounds for use as nmda modulators | |
| CA3041077C (en) | Oxysterols and methods of use thereof | |
| HK40102021A (en) | Oxysterols and methods of use thereof | |
| HK40083913A (en) | Oxysterols and methods of use thereof | |
| HK40006820A (en) | Oxysterols and methods of use thereof | |
| HK40006820B (en) | Oxysterols and methods of use thereof | |
| HK40006309A (en) | Oxysterols and methods of use thereof | |
| HK40006309B (en) | Oxysterols and methods of use thereof | |
| HK40004830B (en) | C7 substituted oxysterols and these compounds for use as nmda modulators | |
| HK40004830A (en) | C7 substituted oxysterols and these compounds for use as nmda modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240405 |
|
| EEER | Examination request |
Effective date: 20240405 |
|
| EEER | Examination request |
Effective date: 20240405 |
|
| EEER | Examination request |
Effective date: 20240405 |